Ftse Mib
36.471,75
0,12%
DAX
21.732,05
0,01%
S&P 500
6.040,53
-0,50%
NASDAQ
19.627,44
-0,28%
Bitcoin
99.489,11
-1,17%
Pepperstone
Advertisement
Registration Strip Icon for alerts Registrati per avvisi in tempo reale, portafoglio personalizzato e movimenti di mercato.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ CytomX Therapeutics Inc (CTMX) CytomX Therapeutics Inc (CTMX) Notizie

CytomX Therapeutics Inc

CTMX
0,87
-0,005 (-0,57%)
01 Feb 2025 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
08/1/202514:00GLOBECytomX Therapeutics to Present at the 43rd Annual J.P...
06/1/202522:10EDGAR2Form 8-K - Current report
06/1/202522:05GLOBECytomX Therapeutics Announces 2025 Strategic Pipeline..
27/11/202414:00GLOBECytomX Therapeutics to Present at the 36th Annual Piper..
14/11/202421:03EDGAR2Form SC 13G/A - Statement of Beneficial Ownership by Certain..
07/11/202422:10GLOBECytomX Therapeutics Reports Third Quarter 2024 Financial..
07/11/202422:09EDGAR2Form 8-K - Current report
07/11/202422:02EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
31/10/202413:00GLOBECytomX Therapeutics to Report Third Quarter 2024 Financial..
09/9/202414:00GLOBECytomX Therapeutics Announces First Patient Dosed with..
04/9/202414:00GLOBECytomX Therapeutics to Present at Upcoming September..
23/8/202400:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/8/202400:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/8/202423:59EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/8/202423:58EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/8/202406:15EDGAR2Form EFFECT - Notice of Effectiveness
09/8/202422:06EDGAR2Form S-3 - Registration statement under Securities Act of..
08/8/202422:10GLOBECytomX Therapeutics Reports Second Quarter 2024 Financial..
08/8/202422:08EDGAR2Form 8-K - Current report
08/8/202422:03EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
01/8/202414:00GLOBECytomX Therapeutics to Report Second Quarter 2024 Financial..
18/6/202414:00GLOBECytomX Therapeutics to Present at the H.C. Wainwright 2nd..
17/6/202422:35EDGAR2Form 8-K - Current report
17/6/202422:15GLOBECytomX Therapeutics Promotes Chris Ogden to Chief Financial..
14/6/202422:24EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/5/202422:05GLOBECytomX Therapeutics to Present at the Jefferies Global..
17/5/202423:36EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/5/202423:36EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/5/202423:34EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/5/202423:32EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/5/202423:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/5/202422:01EDGAR2Form 8-K - Current report
16/5/202422:15GLOBECytomX Therapeutics Announces New Employment Inducement..
13/5/202422:00EDGAR2Form SC 13G - Statement of acquisition of beneficial..
08/5/202422:41EDGAR2Form 8-K - Current report
08/5/202422:10GLOBECytomX Therapeutics Announces Positive Initial Phase 1a Dose..
08/5/202422:04EDGAR2Form 8-K - Current report
08/5/202422:01EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/5/202422:15GLOBECytomX Therapeutics Announces Clinical Collaboration with..
01/5/202414:00GLOBECytomX Therapeutics to Report First Quarter 2024 Results and..
08/4/202414:00GLOBECytomX Therapeutics Announces First Patient Dosed with..
03/4/202414:00GLOBECytomX Therapeutics Announces Nomination of Second Clinical..
21/3/202413:00GLOBECytomX Therapeutics Appoints Dr. Zhen Su to Board of..
18/3/202413:00GLOBECytomX Therapeutics Announces Milestone Achievement in..
11/3/202421:30EDGAR2Form S-8 - Securities to be offered to employees in employee..
11/3/202421:10GLOBECytomX Therapeutics Reports 2023 Financial Results and..
11/3/202421:02EDGAR2Form 8-K - Current report
11/3/202421:00EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
11/3/202411:39IHMARKETNEWSU.S. Index Futures Dip Ahead of Inflation Data and Oracle’s..
04/3/202414:00GLOBECytomX Therapeutics to Report Fourth Quarter and Full Year..
Apertura: 0,88 Min: 0,84 Max: 0,9191
Chiusura: 0,875

La tua Cronologia

NASDAQ
CTMX
CytomX Therapeutics
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network

Rimuovi gli annunci

Iscriviti per un'esperienza senza pubblicità

Nessuna pubblicità

Prova adesso

Conserva gli annunci